(2S)-N-[(2S)-1-[[(2S)-1-[[(2R)-1-[[(3S,12S,15S,18S,21R,24S,26R)-21-benzyl-18-(3-carbamimidamidopropyl)-12-carbamoyl-26-hydroxy-15-(1H-indol-3-ylmethyl)-2,6,14,17,20,23-hexaoxo-1,7,13,16,19,22-hexazabicyclo[22.3.0]heptacosan-3-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-2-[[(2S)-2-[[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[4-(heptadecanoylsulfamoyl)butanoylamino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]pentanediamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-N-[(2S)-1-[[(2S)-1-[[(2R)-1-[[(3S,12S,15S,18S,21R,24S,26R)-21-benzyl-18-(3-carbamimidamidopropyl)-12-carbamoyl-26-hydroxy-15-(1H-indol-3-ylmethyl)-2,6,14,17,20,23-hexaoxo-1,7,13,16,19,22-hexazabicyclo[22.3.0]heptacosan-3-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-2-[[(2S)-2-[[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[4-(heptadecanoylsulfamoyl)butanoylamino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]pentanediamide
• 化学式: C₁₁₈H₁₈₅N₂₉O₃₃S
• 分子量: 2570.0
• InChiKey: WWUOZRGMRLYGND-ZVDKHORYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  181
• 可旋转键数：
  88
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  947
• 氢给体数：
  30
• 氢受体数：
  36

文献信息

• Novel Peptides for Use in the Treatment of Obesity
  申请人：Sensfuss Ulrich

  公开号：US20100056433A1

  公开（公告）日：2010-03-04

  The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

  本发明涉及一种新型肽化合物，其有效调节一个或多个黑素皮质素受体类型，以及将该化合物用于治疗、包括将该化合物用于治疗需要该化合物的患者的治疗方法，以及将该化合物用于制造药物的用途。本发明的化合物在治疗肥胖症以及与肥胖症相关的各种疾病或症状方面具有特殊的兴趣。